<DOC>
	<DOCNO>NCT01446159</DOCNO>
	<brief_summary>Study evaluate safety , tolerability , antitumor activity , pharmacology MEDI-573 combination AI adult subject HR+ , HER2-negative MBC .</brief_summary>
	<brief_title>Study MEDI-573 Plus Standard Endocrine Therapy Women With Hormone-sensitive Metastatic Breast Cancer</brief_title>
	<detailed_description>This Phase 1b/2 , multicenter , open-label study evaluate safety , tolerability , antitumor activity , pharmacology MEDI-573 combination AI adult subject HR+ , HER2-negative MBC . This study 2 phase : dose-evaluation phase ( Phase 1b ) randomization phase ( Phase 2 ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>Histologicallyconfirmed MBC deem amenable curative surgery curative radiation therapy Tumors positive ER , PgR , Tumors must negative HER2 ( FISH , CISH IHC ) Female gender age ≥ 18 year time study entry Postmenopausal Karnofsky Performance Status ≥ 70 Life expectancy ≥ 6 month Subjects receive prior chemotherapy , hormonal therapy , immunotherapy biologic therapy advance metastatic disease follow exception : Prior adjuvant therapy AI and/or tamoxifen allow , provide treatment end least 2 week prior first dose MEDI573 Prior neoadjuvant and/or adjuvant chemotherapy breast cancer allow Extensive symptomatic visceral disease include hepatic involvement pulmonary lymphangitic spread tumor , disease consider investigator rapidly progress life threatening ( eg , subject intend chemotherapy ) Active brain metastasis exception subject treat asymptomatic evidence CNS progression least 4 week first dose MEDI573 Evidence ongoing spinal cord compression leptomeningeal carcinomatosis Unresolved toxicities prior therapy exception alopecia resolve ≤ Grade 1 time start study treatment Previous treatment agent target IGF receptor History allergy reaction attribute compound chemical biologic composition similar MEDI573 AI History another invasive malignancy within 5 year except curatively resect nonmelanoma skin cancer carcinoma situ cervix Poorly control diabetes mellitus</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>MEDI-573 , breast cancer , metastatic , aromatase inhibitor , anti-IGF</keyword>
</DOC>